Biotest AG
- ISIN DE0005227235
- Country Deutschland
Company profile
The most important raw material for our pharmaceuticals is human blood plasma, which we process into effective and highly purified drugs in one of our world leading fractionation facilities in Europe. These medications are used to treat life-threatening diseases such as blood coagulation disorders (haemophilia), severe infections and immune system disorders.
Management
Peter started his career as an assistant Professor at the University of Leuven in Belgium, was a reserve officer at the Belgian Air Force and worked in the semiconductor division of Air Products in Pennsylvania, US. He holds a Master of Science degree in Electro-Mechanical Engineering, a Master degree in Applied Economics and Business Degree from INSEAD, France. Peter Janssen was born in 1966.
Ainhoa Mendizabal has been a member of the Board of Management of Biotest AG since February 2023. As Chief Financial Officer, Ms Mendizabal is responsible within the Biotest Group for the areas of finance including the treasury and tax department, controlling, investor relations and insurance. Previously, Ms Mendizabal held various executive and managerial positions in the Grifols Group in Germany and in Europe. Ms Mendizabal also worked for several years in an international consulting firm in the area of CFO Services and Enterprise Applications. From there, she moved to Talecris Biotherapeutics GmbH before Talecris was acquired by Grifols S.A.. Ainhoa Mendizabal holds a dual Master of Business Administration in Germany and Spain. Ms Mendizabal was born in 1972.
In January 2022 Dr. Schüttrumpf has been appointed to the Board of Management at Biotest AG. Since 2015 he was responsible for the Research & Development Division, and since 2012 for Global Research at Biotest AG. Before, Dr. Schüttrumpf worked at different academic and non-government organizations in Germany and the US, among those the German Red Cross Blood Donor Service, the Goethe University Frankfurt, the University Hospital of Essen, The Children’s Hospital of Philadelphia, and the University of Pennsylvania. Dr. Schüttrumpf has studied medicine, is specialized in transfusion medicine and haemostaseology, and has a Master of Business Administration from IMD Business School. Dr. Jörg Schüttrumpf was born in 1974.
IR contact
Dr. Monika Bauman (Buttkereit)
Head of Investor Relations Biotest AG
Landsteinerstraße 5
D-63303 Dreieich
Phone: +49 (0) 61 03 – 801 4406
Fax: +49 (0) 61 03 – 801 347
E-Mail: ir@biotest.com